These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38524878)

  • 41. Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
    Samuels JM; Niswender KD; Roumie CL; Spann MD; Flynn CR; Ye F; Blankush J; Irlmeier R; Funk LM; Patel MB
    Diabetes Obes Metab; 2024 Sep; 26(9):3906-3913. PubMed ID: 38934217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy comparison of medications approved for chronic weight management.
    Kumar RB; Aronne LJ
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.
    Polyzos SA; Goulis DG; Giouleme O; Germanidis GS; Goulas A
    Curr Obes Rep; 2022 Sep; 11(3):166-179. PubMed ID: 35501557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525
    [No Abstract]   [Full Text] [Related]  

  • 45. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
    Son JW; Kim S
    Diabetes Metab J; 2020 Dec; 44(6):802-818. PubMed ID: 33389955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
    Wilding JPH
    Clin Obes; 2018 Jun; 8(3):211-225. PubMed ID: 29689646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world primary nonadherence to antiobesity medications.
    Kan H; Bae JP; Dunn JP; Buysman EK; Gronroos NN; Swindle JP; Bengtson LGS; Ahmad N
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1099-1108. PubMed ID: 37594848
    [No Abstract]   [Full Text] [Related]  

  • 48. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K; Braverman-Panza J
    J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current and emerging medications for overweight or obesity in people with comorbidities.
    Fujioka K
    Diabetes Obes Metab; 2015 Nov; 17(11):1021-32. PubMed ID: 26040215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacotherapy for obesity in individuals with type 2 diabetes.
    Chukir T; Shukla AP; Saunders KH; Aronne LJ
    Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current State of Pharmacotherapy in Obesity].
    Kim WJ
    Korean J Gastroenterol; 2024 Mar; 83(3):94-101. PubMed ID: 38522852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Past, Present, and Future of Pharmacologic Therapy in Obesity.
    Rodríguez JE; Campbell KM
    Prim Care; 2016 Mar; 43(1):61-7, viii. PubMed ID: 26896200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
    Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The risk of cardiovascular complications with current obesity drugs.
    Chao AM; Wadden TA; Berkowitz RI; Quigley K; Silvestry F
    Expert Opin Drug Saf; 2020 Sep; 19(9):1095-1104. PubMed ID: 32750250
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.